A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol

A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol

Abstract Background Concurrent chemoradiotherapy is a standard modality for locally advanced esophageal squamous cell carcinoma (ESCC) patients. Cisplatin combined with 5-fluorouracil continuous infusion (PF) remains the standard concurrent chemotherapy regimen. However, radiotherapy concurrent with...

Full description

Bibliographic Details
Main Authors: Yun Chen, Zhengfei Zhu, Weixin Zhao, Ling Li, Jinjun Ye, Chaoyang Wu, Huarong Tang, Qin Lin, Jiancheng Li, Yi Xia, Yunhai Li, Jialiang Zhou, Kuaile Zhao
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Radiation Oncology
Subjects:
Esophageal squamous cell carcinoma
Concurrent chemoradiotherapy
Paclitaxel
Cisplatin
5-fluorouracil
Online Access:http://link.springer.com/article/10.1186/s13014-018-0979-0

Internet

http://link.springer.com/article/10.1186/s13014-018-0979-0

Similar Items